Arecor Joins Elite Investor Roadshow to China

ARECOR LIMITED (“Arecor” or “the Company”) ARECOR JOINS ELITE INVESTOR ROADSHOW TO CHINA “Arecor has joined the London Stock Exchange Group’s latest ELITE mission to China for aspiring companies and will participate in investor roadshow events, in Shenzhen and Hong Kong, between 15th – 18th October 2018” Cambridge, UK., 15 October 2018: Arecor Limited (“the […]

AmpliPhi Biosciences Announces Pricing of $6.6 Million Underwritten Public Offering

CATEGORY: Featured Friday, October 12, 2018 6:00 am EDT SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEAM: APHB SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE AMERICAN: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for patients with serious and life-threatening antibiotic-resistant bacterial infections, today announced the pricing of an underwritten public offering of 16,537,500 […]

AmpliPhi Biosciences Announces Presentation of Positive Clinical Data From its Expanded Access Program for Serious S. aureus Infections at IDWeek 2018 Conference

 13 patients with serious and life-threatening S. aureus infections were treated with AB-SA01 at the Westmead Hospital in Sydney under AmpliPhi’s expanded access program  Patients suffered from severe S. aureus bacteremia and sepsis, including infective endocarditis and prosthetic valve endocarditis  83% (10 out of 12) patients in the modified intent-to-treat (mITT) population achieved treatment success […]

AVITA Medical Announces Presentation of RECELL® System Effectiveness and Safety at Eastern Great Lakes Burn Conference

Clinical results demonstrate point-of-care regenerative medicine technology benefits in treatment of second- and third-degree burns using Spray-On Skin™ Cells Valencia, Calif., USA, and Melbourne, Australia, 27 September 2018 — AVITA Medical (ASX: AVH, OTCQX:AVMXY), a global regenerative medicinecompany, today announced that the results from two U.S. pivotalclinical trials demonstrating the effectiveness and clinical benefits of […]

Interim results for the six months ended 30 June 2018

Destiny Pharma plc (“Destiny Pharma” or the “Company”)   Interim results for the six months ended 30 June 2018   Clinical progress and pipeline expansion in dermal infections; well-funded through to H2 2020   Brighton, United Kingdom – 26 September 2018 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development […]

Destiny Pharma announces appointment of Chief Medical Officer

Destiny Pharma plc (“Destiny” or “the Company”) Dr Jesús González brings extensive experience in the clinical development of anti-infectives, as the Company prepares to initiate a Phase 2b trial for lead asset Brighton, United Kingdom – 26 September 2018 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel antimicrobial […]

AVITA Medical Announces Receipt of $1 Million Research and Development Tax Credit

Valencia, Calif., USA, and Melbourne, Australia, 26 September 2018 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that it has received a Research and Development Tax Incentive cash rebate from the Australian Tax Office in the amount of A$1.0 million for the year ending 30 June 2017. The R&D […]

Amarin Soars as Fish Oil Pill Cuts Risk of Strokes in Long-Awaited Study

Xconomy New York — Amarin Soars as Fish Oil Pill Cuts Risk of Strokes in Long-Awaited Study Can fish oil help prevent, or reduce the risk of heart disease? Several studies have failed to show that it can. But Amarin this morning is releasing data from a massive study showing that its prescription-grade fish oil […]

AmpliPhi Biosciences to Present Clinical Case Series Data at IDWeek 2018

Professor Jonathan Iredell to present data from AmpliPhi Biosciences’ ongoing expanded access program for bacteriophage product candidates AB-SA01 (targeting S. aureus) and AB-PA01 (targeting P. aeruginosa) Monday, September 24, 2018 6:50 am EDT PUBLIC COMPANY INFORMATION: NYSEAM: APHB SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics […]

AVITA Medical Announces FDA Approval of the RECELL® System for the Treatment of Severe Burns in the U.S.

Point-of-care regenerative medicine technology approved to treat secondand third-degree burns using Spray-On Skin™ Cells product U.S. market launch planned for 4th calendar quarter 2018. Target market for burns approximates USD $200 million Valencia, Calif., USA, and Melbourne, Australia, 21 September 2018 — AVITA Medical (ASX: AVH, OTCQX:AVMXY), a global regenerative medicine company, today announced that […]